With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.63927-22-0,8-Bromoisoquinoline,as a common compound, the synthetic route is as follows.
63927-22-0, To a 100 mL round-bottomed flask equipped with condenser and N2 inlet were added 2.46 g (11.8 mmol) 8-bromoisoquinoline, 1.68 mL (14.1 mmol) benzyl bromide, and 10 mL ethanol. The solution was heated at reflux for 6 hr, cooled, and evaporated. The oil was dissolved in 50 mL methanol, and 1.73 g (27.6 mmol) sodium cyanoborohydride was added. The solution was stirred at room temperature for 5 days, then diluted with water and extracted with three portions of ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and evaporated. The residue was chromatographed on silica gel using hexane/ethyl acetate to afford 1.98 g (59percent) of an oil. 1H-NMR (delta, CDCl3): 2.68 (m, 2H), 2.88 (m, 2H), 3.68 (m, 2H), 3.75 (m, 2H), 7.0-7.1 (m, 2H), 7.2-7.4 (m, 6H).
63927-22-0 8-Bromoisoquinoline 9859134, aisoquinoline compound, is more and more widely used in various fields.
Reference：
Patent; Pfizer Inc; US2004/254193; (2004); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem